(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-0.05%) $82.59
(1.67%) $2.06
(-0.68%) $2 341.60
(-1.50%) $27.25
(-0.26%) $959.00
(0.20%) $0.934
(0.34%) $11.02
(0.16%) $0.797
(0.01%) $93.31
-2.27% $ 3.02
Live Chart Being Loaded With Signals
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies...
Stats | |
---|---|
Volumen de hoy | 1.01M |
Volumen promedio | 167 616 |
Capitalización de mercado | 108.71M |
EPS | $0 ( 2024-03-28 ) |
Last Dividend | $0.130 ( 2015-11-06 ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.25 |
ATR14 | $0.0570 (1.89%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Leonard Braden Michael | Buy | 170 589 | Common Stock, par value $0.001 per share |
2024-03-18 | Leonard Braden Michael | Buy | 113 777 | Common Stock, par value $0.001 per share |
2024-03-15 | Leonard Braden Michael | Buy | 0 | Common Stock, par value $0.001 per share |
2024-03-15 | Leonard Braden Michael | Sell | 0 | Common Stock, par value $0.001 per share |
2024-03-04 | Gaiero David G | Buy | 2 373 | Common Stock |
INSIDER POWER |
---|
11.44 |
Last 95 transactions |
Buy: 1 923 587 | Sell: 1 715 632 |
Volumen Correlación
Cyteir Therapeutics, Inc. Correlación
10 Correlaciones Más Positivas | |
---|---|
EBACU | 0.891 |
TCMD | 0.875 |
ECHO | 0.873 |
TZPSU | 0.872 |
WULF | 0.871 |
TZPS | 0.869 |
JNCE | 0.869 |
MBTCU | 0.868 |
RBNC | 0.866 |
NLTX | 0.865 |
10 Correlaciones Más Negativas | |
---|---|
VIASP | -0.896 |
STBA | -0.894 |
CMBM | -0.893 |
FBNC | -0.893 |
MMAC | -0.893 |
TRST | -0.892 |
LSAQ | -0.891 |
CVCY | -0.891 |
OPI | -0.891 |
VGFC | -0.891 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Cyteir Therapeutics, Inc. Correlación - Moneda/Commodity
Cyteir Therapeutics, Inc. Finanzas
Annual | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-1.38M (0.00 %) |
EPS: | $-1.250 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-1.38M (0.00 %) |
EPS: | $-1.250 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.201 |
FY | 2020 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.070 |
Financial Reports:
No articles found.
Cyteir Therapeutics, Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0100 | 2009-08-06 |
Last Dividend | $0.130 | 2015-11-06 |
Next Dividend | $0 | N/A |
Payout Date | 2015-11-25 | |
Next Payout Date | N/A | |
# dividends | 26 | -- |
Total Paid Out | $2.66 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.76 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.236 | 1.200 | -7.86 | -9.43 | [0 - 0.3] |
returnOnEquityTTM | -0.231 | 1.500 | -3.68 | -5.52 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 21.89 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 21.66 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 21.65 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.000122 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 39.40 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.716 | 2.00 | -0.239 | -0.477 | [0 - 30] |
freeCashFlowPerShareTTM | -0.724 | 2.00 | -0.362 | -0.724 | [0 - 20] |
debtEquityRatioTTM | 0.000128 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1 611.81 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 2.08 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.52 | 1.000 | -0.457 | 0 | [1 - 100] |
returnOnEquityTTM | -0.231 | 2.50 | -2.37 | -5.52 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.724 | 2.00 | -0.241 | -0.724 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.716 | 2.00 | -0.239 | -0.477 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -0.983 |
Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico